

Volume 47, Number 20  
Pages 1477–1568

October 17, 2022

# MISSOURI



# REGISTER

John R. Ashcroft  Secretary of State

The *Missouri Register* is an official publication of the state of Missouri, under the authority granted to the secretary of state by sections 536.015 and 536.033, RSMo. Reproduction of rules is allowed; however, no reproduction shall bear the name *Missouri Register* or “official” without the express permission of the secretary of state.

The *Missouri Register* is published semi-monthly by

**SECRETARY OF STATE**

**John R. Ashcroft**

Administrative Rules Division

James C. Kirkpatrick State Information Center

600 W. Main

Jefferson City, MO 65101

(573) 751-4015

EDITOR-IN-CHIEF

CURTIS W. TREAT

•

MANAGING EDITOR

STEPHANIE MARTIN

•

PUBLICATION SPECIALIST II

JACQUELINE D. WHITE

•

EDITOR II

VONNE KILBOURN

•

EDITOR

JENNIFER ALEX MOORE

•

ADMINISTRATIVE AIDE III

TAMMY WINKELMAN

ISSN 0149-2942

The *Missouri Register* and *Code of State Regulations* (CSR) are available on the Internet. The Register address is [sos.mo.gov/adrules/moreg/moreg](http://sos.mo.gov/adrules/moreg/moreg) and the CSR is [sos.mo.gov/adrules/csr/csr](http://sos.mo.gov/adrules/csr/csr). The Administrative Rules Division may be contacted by email at [rules@sos.mo.gov](mailto:rules@sos.mo.gov).

The secretary of state's office makes every effort to provide program accessibility to all citizens without regard to disability. If you desire this publication in alternate form because of a disability, please contact the Division of Administrative Rules, PO Box 1767, Jefferson City, MO 65102, (573) 751-4015. Hearing impaired citizens should contact the director through Missouri relay, (800) 735-2966.



## IN THIS ISSUE:

### EMERGENCY RULES

<b>Department of Health and Senior Services</b>	
Division of Regulation and Licensure . . . . .	1481

### PROPOSED RULES

<b>Department of Conservation</b>	
Conservation Commission . . . . .	1501
<b>Missouri Department of Transportation</b>	
Missouri Highways and Transportation Commission . . . . .	1508
Highway Safety and Traffic Division . . . . .	1515
<b>Department of Health and Senior Services</b>	
Division of Community and Public Health . . . . .	1521
Division of Regulation and Licensure . . . . .	1522
<b>Department of Commerce and Insurance</b>	
Committee for Professional Counselors . . . . .	1544

### ORDERS OF RULEMAKING

<b>Department of Conservation</b>	
Conservation Commission . . . . .	1546
<b>Department of Social Services</b>	
MO HealthNet Division . . . . .	1546
<b>Department of Commerce and Insurance</b>	
Missouri Dental Board . . . . .	1547
Board of Examiners for Hearing Instrument Specialists . . . . .	1547
State Board of Pharmacy . . . . .	1548
Board of Private Investigator and Private Fire Investigator Examiners . . . . .	1548
State Committee for Social Workers . . . . .	1548

<b>DISSOLUTIONS</b> . . . . .	1549
-------------------------------	------

### SOURCE GUIDES

<b>RULE CHANGES SINCE UPDATE</b> . . . . .	1555
<b>EMERGENCY RULES IN EFFECT</b> . . . . .	1559
<b>EXECUTIVE ORDERS</b> . . . . .	1560
<b>REGISTER INDEX</b> . . . . .	1562

Register Filing Deadlines	Register Publication Date	Code Publication Date	Code Effective Date
June 1, 2022 June 15, 2022	July 1, 2022 July 15, 2022	July 31, 2022 July 31, 2022	August 30, 2022 August 30, 2022
July 1, 2022 July 15, 2022	August 1, 2022 August 15, 2022	August 31, 2022 August 31, 2022	September 30, 2022 September 30, 2022
August 1, 2022 August 15, 2022	September 1, 2022 September 15, 2022	September 30, 2022 September 30, 2022	October 30, 2022 October 30, 2022
September 1, 2022 September 15, 2022	October 3, 2022 October 17, 2022	October 31, 2022 October 31, 2022	November 30, 2022 November 30, 2022
October 3, 2022 October 17, 2022	November 1, 2022 November 15, 2022	November 30, 2022 November 30, 2022	December 30, 2022 December 30, 2022
November 1, 2022 November 15, 2022	December 1, 2022 December 15, 2022	December 31, 2022 December 31, 2022	January 30, 2023 January 30, 2023
December 1, 2022 December 15, 2022	January 3, 2023 January 17, 2023	January 29, 2023 January 29, 2023	February 28, 2023 February 28, 2023
January 3, 2023 January 17, 2023	February 1, 2023 February 15, 2023	February 28, 2023 February 28, 2023	March 30, 2023 March 30, 2023

Documents will be accepted for filing on all regular workdays from 8:00 a.m. until 5:00 p.m. We encourage early filings to facilitate the timely publication of the *Missouri Register*. Orders of Rulemaking appearing in the *Missouri Register* will be published in the *Code of State Regulations* and become effective as listed in the chart above. Advance notice of large volume filings will facilitate their timely publication. We reserve the right to change the schedule due to special circumstances. Please check the latest publication to verify that no changes have been made in this schedule. To review the entire year's schedule, please see the website at [sos.mo.gov/adrules/pubsched](https://sos.mo.gov/adrules/pubsched).

## HOW TO CITE RULES AND RSMO

### RULES

The rules are codified in the *Code of State Regulations* in this system—

<b>Title</b>	<b>CSR</b>	<b>Division</b>	<b>Chapter</b>	<b>Rule</b>
3 Department	<i>Code of State Regulations</i>	10- Agency division	4 General area regulated	115 Specific area regulated

and should be cited in this manner: 3 CSR 10-4.115.

Each department of state government is assigned a title. Each agency or division in the department is assigned a division number. The agency then groups its rules into general subject matter areas called chapters and specific areas called rules. Within a rule, the first breakdown is called a section and is designated as (1). Subsection is (A) with further breakdown into paragraphs 1., subparagraphs A., parts (I), subparts (a), items I. and subitems a.

The rule is properly cited by using the full citation; for example, 3 CSR 10-4.115, NOT Rule 10-4.115.

Citations of RSMo are to the *Missouri Revised Statutes* as of the date indicated.

### ***Code and Register on the Internet***

The *Code of State Regulations* and *Missouri Register* are available on the Internet.

The *Code* address is [sos.mo.gov/adrules/csr/csr](http://sos.mo.gov/adrules/csr/csr)

The *Register* address is [sos.mo.gov/adrules/moreg/moreg](http://sos.mo.gov/adrules/moreg/moreg)

These websites contain rulemakings and regulations as they appear in the *Code* and *Registers*.

Rules appearing under this heading are filed under the authority granted by section 536.025, RSMo. An emergency rule may be adopted by an agency if the agency finds that an immediate danger to the public health, safety, or welfare, or a compelling governmental interest requires emergency action; follows procedures best calculated to assure fairness to all interested persons and parties under the circumstances; follows procedures which comply with the protections extended by the Missouri and the United States Constitutions; limits the scope of such rule to the circumstances creating an emergency and requiring emergency procedure, and at the time of or prior to the adoption of such rule files with the secretary of state the text of the rule together with the specific facts, reasons, and findings which support its conclusion that there is an immediate danger to the public health, safety, or welfare which can be met only through the adoption of such rule and its reasons for concluding that the procedure employed is fair to all interested persons and parties under the circumstances.

Rules filed as emergency rules may be effective not less than ten (10) business days after filing or at such later date as may be specified in the rule and may be terminated at any time by the state agency by filing an order with the secretary of state fixing the date of such termination, which order shall be published by the secretary of state in the Missouri Register as soon as practicable.

All emergency rules must state the period during which they are in effect, and in no case can they be in effect more than one hundred eighty (180) calendar days or thirty (30) legislative days, whichever period is longer. Emergency rules are not renewable, although an agency may at any time adopt an identical rule under the normal rulemaking procedures.

**Title 19 – DEPARTMENT OF HEALTH AND SENIOR SERVICES**

**Division 30 – Division of Regulation and Licensure  
Chapter 1 – Controlled Substances**

**EMERGENCY AMENDMENT**

**19 CSR 30-1.002 Schedules of Controlled Substances.** The department is amending section (1).

*PURPOSE: This amendment updates the Schedules of Controlled Substances to be consistent with 21 CFR Part 1308.*

*EMERGENCY STATEMENT: The United States Department of Justice Drug Enforcement Administration (DEA) continually evaluates substances to determine their clinical application and potential for abuse. Based on their evaluation, the DEA issues scheduling actions to place substances in the appropriate controlled substance schedules. The majority of these scheduling actions consist of temporarily and permanently scheduling newly-discovered illicit substances in Schedule I. Proper scheduling of these substances allow law enforcement to take action to prevent the further distribution of these substances. Scheduling substances in Schedules II-V allows practitioners to be informed about the potential for addiction/abuse of the substances and prescribe the substances appropriately. Section 195.015, RSMo charges the department with similarly controlling substances as they are controlled under federal law. Section*

*195.015.4 requires the Department of Health and Senior Services to submit emergency rules to the Secretary of State within thirty days of a federal scheduling action to allow for similar inclusion, rescheduling, or deletion of controlled substances with this schedule. While this time frame is difficult to achieve given the various approvals and reviews needed prior to the Department scheduling any rule with the Secretary of State, the Department still acts to effectuate these scheduling actions as quickly as possible. This emergency amendment includes all federal scheduling actions since the last amendment of this rule in 2020. This emergency amendment is necessary to protect Missouri's governmental interest in keeping its controlled substances schedules up-to-date as much as practically possible in order to protect its citizens and to aid law enforcement in its prosecution of those who illegally distribute these substances. As a result, the Department of Health and Senior Services finds a compelling governmental interest, which requires this emergency action. A proposed amendment, which covers the same material, is published in this issue of the Missouri Register. The scope of this emergency amendment is limited to the circumstances creating the emergency and complies with the protections extended in the Missouri and United States Constitutions. The Department of Health and Senior Services believes this emergency amendment is fair to all interested persons and parties under the circumstances. Subject to section 536.025, this emergency amendment was filed September 12, 2022, becomes effective October 3, 2022, and expires March 31, 2023.*

(1) Schedules of Controlled Substances.

(A) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Drug Enforcement Administration (DEA) Controlled Substances Code Number set forth opposite it.

1. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

- A. Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide) 9815
- B. Acetylmethadol 9601
- C. Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) 9821
- D. N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: acryl fentanyl, acryloylfentanyl) 9811
- E. AH-7921(3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl] benzamide) 9551
- F. Allylprodine 9602
- G. Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-acetylmethadol levothadyl acetate or LAAM) 9603
- H. Alphameprodine 9604

I. Alphamethadol	9605	LL. Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl) (phenyl)carbamate)	9851
J. Alpha-methylfentanyl (N-1-(alphamethyl-beta-phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4 ((N-propanilido) piperidine)	9814	MM. N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: 4-fluoroisobutyryl fentanyl, para-fluoroisobutyryl fentanyl)	9824
K. Alpha-methylthiofentanyl (N-(1-methyl-2-(2-thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide)	9832	NN. 2'-Fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl) piperidin-4-yl)-N-(2-fluorophenyl) propionamide (Other names: 2'-fluoro 2-fluorofentanyl)	9855
L. Benzethidine	9606	OO. N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: furanyl fentanyl)	9834
M. Betacetylmethadol	9607	PP. Furethidine	9626
N. Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-phenylpropanamide)	9830	QQ. Hydroxypethidine	9627
O. Beta-hydroxy-3-methylfentanyl (other name: N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide)	9831	RR. N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (Other name: isobutyryl fentanyl)	9827
P. N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-4-yl]-N-phenylpropionamide (Other names: beta-hydroxythiofentanyl)	9836	SS. <b>Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl) ethan-1-amine)</b>	<b>9614</b>
Q. Betameprodine	9608	[SS.]TT. Ketobemidone	9628
R. Betamethadol	9609	[TT.]UU. Levomoramide	9629
S. beta-Methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl) propionamide (Other name: $\beta$ -methyl fentanyl)	9856	[UU.]VV. Levophenacetylmorphan	9631
T. beta'-Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (Other names: $\beta'$ -phenyl fentanyl; 3-phenylpropanoyl fentanyl)	9842	[VV.]WW. Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9825
U. Betaprodine	9611	[WW.]XX. 4'-Methyl acetyl fentanyl (N-(1-(4-methylphenethyl) piperidin-4-yl)-N-phenylacetamide)	9819
V. Clonitazene	9612	[XX.]YY. 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide), its optical and geometric isomers, salts, and salts of isomers	9813
W. Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide)	9844	[YY.]ZZ. 3-Methylthiofentanyl (N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide)	9833
X. N-(1-phenethylpiperidin-4-yl)-N-Phenylcyclopentanecarboxamide (Other name: cyclopentyl fentanyl)	9847	[ZZ.]AAA. Morpheridine	9632
Y. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide)	9845	[AAA.]BBB. MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
Z. Dextromoramide	9613	[BBB.]CCC. MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl) piperazine)	(9560)
AA. Diampromide	9615	[CCC.]DDD. Noracymethadol	9633
BB. Diethylthiambutene	9616	[DDD.]EEE. Norlevorphanol	9634
CC. Difenoxyin	9168	[EEE.]FFF. Normethadone	9635
DD. Dimenoxadol	9617	[FFF.]GGG. Norpipanone	9636
EE. Dimepheptanol	9618		
FF. Dimethylthiambutene	9619		
GG. Dioxaphetyl butyrate	9621		
HH. Dipipanone	9622		
II. Ethylmethylthiambutene	9623		
JJ. Etonitazene	9624		
KK. Etoxeridine	9625		

[GGG.]HHH. N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other name: ocfentanil)	9838	[SSS.]TTT. para-Methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (Other Name: 4-methylfentanyl)	9817
[HHH.]III. ortho-Fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide)	9852	[TTT.]UUU. PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine)	9663
[III.]JJJ. ortho-Fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (Other Name: 2-fluorobutyryl fentanyl)	9846	[UUU.]VVV. Phenadoxone	9637
[JJJ.]KKK. ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide); other name: 2-fluorofentanyl)	9816	[VVV.]WWW. Phenampromide	9638
[KKK.]LLL. ortho-Fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)	9853	[WWW.]XXX. Phenomorphan	9647
[LLL.]MMM. ortho-Methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (Other name: 2-methyl acetylfentanyl)	9848	[XXX.]YYY. Phenoperidine	9641
[MMM.]NNN. ortho-Methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (Other name: 2-methyl methoxyacetyl fentanyl)	9820	[YYY.]ZZZ. Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (Other name: benzoyl fentanyl)	9841
[NNN.]OOO. N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (Other name: para-chloroisobutyryl fentanyl)	9826	[ZZZ.]AAAA. Piritramide	9642
[OOO.]PPP. para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)	9823	[AAAA.]BBBB. Proheptazine	9643
[PPP.]QQQ. Para-fluorofentanyl(N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)propanamide)	9812	[BBBB.]CCCC. Properidine	9644
[QQQ.]RRR. para-Fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide)	9854	[CCCC.]DDDD. Propiram	9649
[RRR.]SSS. para-Methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide)	9837	[DDDD.]EEEE. Racemoramide	9645
		[EEEE.]FFFF. N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other name: tetrahydrofuranlyl fentanyl)	9843
		[FFFF.]GGGG. Thiofentanyl (N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide)	9835
		[GGGG.]HHHH. Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl)	9839
		[HHHH.]IIII. Tilidine	9750
		[IIII.]JJJJ. Trimeperidine	9646
		2. Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:	
		A. Acetorphine	9319
		B. Acetyldihydrocodeine	9051
		C. Benzylmorphine	9052
		D. Codeine methylbromide	9070
		E. Codeine-N-Oxide	9053
		F. Cyprenorphine	9054
		G. Desomorphine	9055
		H. Dihydromorphine	9145
		I. Drotebanol	9335
		J. Etorphine (except hydrochloride salt)	9056
		K. Heroin	9200
		L. Hydromorphenol	9301
		M. Methylodesorphine	9302
		N. Methyl dihydromorphine	9304
		O. Morphine methylbromide	9305
		P. Morphine methylsulfonate	9306
		Q. Morphine-N-Oxide	9307

R. Myrophine	9308	M. 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2)	7385
S. Nicocodeine	9309	N. 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	7518
T. Nicomorphine	9312	O. 2-(4-Isopropylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-4)	7532
U. Normorphine	9313	P. 4-methoxyamphetamine	7411
V. Pholcodine	9314	Some trade or other names: 4-methoxy-amethylphenethylamine; paramethoxyamphetamine; PMA;	
W. Thebacon	9315	Q. 5-methoxy-3,4-methylenedioxyamphetamine	7401
3. Opiate Similar Synthetic Substances. Substances scheduled by the United States Drug Enforcement Administration as substances that share a pharmacological profile similar to fentanyl, morphine, and other synthetic opioids, unless specifically excepted or unless listed in another schedule. These substances are –		R. 4-methyl-2,5-dimethoxyamphetamine	7395
A. Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)	9822	Some trade and other names: 4-methyl-2, 5- dimethoxy-amethylphenethylamine; DOM; and STP;	
B. U-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)	9547	S. 3,4-methylenedioxyamphetamine	7400
C. N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (Other name: valeryl fentanyl)	9840	T. 3,4-methylenedioxy-methamphetamine(MDMA)	7405
4. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (For purposes of paragraph (1)(A)4. of this rule only, the term isomer includes the optical, position, and geometric isomers.):		U. 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, and MDEA)	7404
A. Alpha-ethyltryptamine	7249	V. N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine and N-hydroxy MDA)	7402
Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethenamine; 3-(2-aminobutyl)indole; alpha-ET; and AET;		W. 3,4,5-trimethoxyamphetamine	7390
B. 4-bromo-2,5-dimethoxyamphetamine	7391	X. 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine	7431
Some trade or other names: 4-bromo-2, 5- dimethoxy-amethylphenethylamine; 4-bromo- 2, 5-DMA;		Y. Alpha-methyltryptamine	7432
C. 4-bromo-2,5-dimethoxyphenethylamine	7392	Z. Bufotenine	7433
D. 2,5-dimethoxyamphetamine	7396	Some trade and other names: 3-(b-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine;	
Some trade or other names: 2,5-dimethoxy-amethylphenethylamine; 2,5-DMA;		AA. Diethyltryptamine	7434
E. 2,5-dimethoxy-4-ethylamphetamine	7399	Some trade and other names: N, N-Diethyltryptamine; DET;	
Some trade or other names: DOET;		BB. Dimethyltryptamine	7435
F. 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7)	7348	Some trade or other names: DMT;	
G. 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	CC. 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeODIPT)	7439
H. 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E )	7509	DD. Ibogaine	7260
I. 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	Some trade and other names: 7-Ethyl- 6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6, 9-methano-5H-pyrido [1',2':1,2] azepino[5,4-b] indole; Tabernanthe iboga;	
J. 2-(2,5-Dimethoxy-4-nitrophenyl) ethanamine (2C-N)	7521	EE. Lysergic acid diethylamide	7315
K. 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	FF. Marihuana	7360
L. 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	Some trade or other names: marijuana;	
		GG. Mescaline	7381
		HH. Parahexyl	7374
		Some trade or other names: 3-Hexyl-1- hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran; Synhexyl;	
		II. Peyote	7415
		Meaning all parts of the plant presently classified botanically as <i>Lophophora williamsii</i> Lemaire, whether growing or not;	



the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or extracts;

JJ. N-ethyl-3-piperidyl benzilate	7482
KK. N-methyl-3-piperidyl benzilate	7484
LL. Psilocybin	7437
MM. Psilocyn	7438
<p>NN. Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis 7370 plant), as well as synthetic equivalents of the substances contained in the cannabis plant or in the resinous extractives of such plant, and/or synthetic substances, derivatives, and their isomers, or both, with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following:</p> <p>(I) 1 cis or trans tetrahydrocannabinol and their optical isomers;</p> <p>(II) 6 cis or trans tetrahydrocannabinol and their optical isomers;</p> <p>(III) 3,4 cis or trans tetrahydrocannabinol and its optical isomers; and</p> <p>(IV) Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions are covered;</p>	
OO. Ethylamine analog of phencyclidine	7455
Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl)-ethylamine, cyclohexamine, PCE;	
PP. Pyrrolidine analog of phencyclidine	7458
Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine PCPy, PHP;	
QQ. Thiophene analog of phencyclidine	7470
Some trade or other names: 1-(1-(2-thienyl)-cyclohexyl)-piperidine, 2-thienyl analog of phencyclidine, TPCP, TCP;	
RR. 1-(1-(2-thienyl)cyclohexyl) pyrrolidine	7473
Some other names: TCPy;	
SS. Salvia divinorum	
TT. Salvinorin A	
UU. 3-Fluoromethcathinone	1233
VV. 4-Fluoromethcathinone	1238
WW. Mephedrone, or 4-methylmethcathinone	1248
XX. Methylenedioxy-pyrovalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone	7535
YY. Methylone, or 3,4-Methylenedioxy-methcathinone	7540
ZZ. Quinolin-8-yl 1-pentyl-1Hindole-3-carboxylate (PB-22; QUPIC)	7222
AAA. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22)	7225
BBB. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (AB-FUBINACA)	7012

CCC. N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA)	7035
DDD. (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other names: UR-144, 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole)	7144
EEE. [1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144, 5-F-UR-144, XLR11, 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole)	7011
FFF. N-(1-adamantyl)-1-pentyl-1Hindazole-3-carboxamide (Other names: APINACA, AKB48)	7048
GGG. 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5)	7538
HHH. 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82)	7537
III. 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)	7536
JJJ. 4-methyl-N-ethylcathinone (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one)	1249
KKK. 4-methyl-alpha-pyrrolidinopropiophenone, (Other names: 4-MePPP; MePPP; 4-methyl-alpha-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one)	7498
LLL. alpha-pyrrolidinopentio-phenone (Other names: alpha-PVP; alpha-pyrrolidinovale-rophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one)	7545
MMM. Butylone (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one)	7541

NNN. Pentedrone (Other names: $\alpha$ -methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one)	1246	YYY. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: ADB-FUBINACA)	7010
OOO. Pentylone (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one)	7542	ZZZ. methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMA-CHMICA, MMB-CHMINACA)	7042
PPP. Naphyrone (Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one)	1258	AAAA. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMA-FUBINACA)	7020
QQQ. $\alpha$ -pyrrolidinobutio-phenone (Other names: $\alpha$ -PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one)	7546	BBBB. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Other names: FUB-AMB, MMB-FUBINACA, AMB-FUBINACA)	(7021)
RRR. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: AB-CHMINACA)	7031	CCCC. 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (ethylone)	7547
SSS. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names: AB-PINACA)	7023	DDDD. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (Other names: NM2201; CBL2201)	7221
TTT. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other names: THJ-2201)	7024	EEEE. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (Other name: 5F-AB-PINACA)	7025
UUU. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: MAB-CHMINACA; ADB-CHMINACA)	7032	FFFF. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (Other names: 4-CN-CUMYLBUTINACA; 4-cyano-CUMYLBUTINACA; 4-CN-CUMYLBINACA; CUMYL-4CNBINACA; SGT-78)	7089
VVV. methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-ADB; 5F-MDMA-PINACA)	7034	GGGG. methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB-CHMICA; AMB-CHMICA)	7044
WWW. methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Other names: 5F-AMB)	7033	HHHH. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Other name: 5F-CUMYL-P7AICA)	7085
XXX. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (Other names: 5F-APINACA, 5F-AKB48)	7049		

III. N-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one)	7543
IIII. methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA)	7043
KKKK. 1-(4-methoxyphenyl)-N-methylpropan-2-amine (Other names: para-methoxymethamphetamine, PMMA)	1245
LLLL. ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (other name: 5F-EDMB-PINACA)	7036
MMMM. methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-Dimethylbutanoate (other names: 5F-MDMB-PICA; 5F-MDMB-2201)	7041
NNNN. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL))	7047
Oooo. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (other names: 5F-CUMYL-PINACA; SGT-25)	7083
PPPP. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone (other name: FUB-144)	7014
QQQQ. N-Ethylhexedrone (Other names: $\alpha$ -ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one)	7246
RRRR. $\alpha$ -Pyrrolidinohexanophenone (Other names: $\alpha$ -PHP; $\alpha$ -pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one)	7544
SSSS. 4-Methyl- $\alpha$ -ethylaminopentiophenone (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one)	7245
TTTT. 4'-Methyl- $\alpha$ -pyrrolidinohexiophenone (Other names: MPHP; 4'-methyl- $\alpha$ -pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one)	7446
UUUU. $\alpha$ -Pyrrolidinoheptaphenone (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one)	7548
VVVV. 4'-Chloro- $\alpha$ -pyrrolidinovalerophenone (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro- $\alpha$ -pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl) pentan-1-one)	7443
WWWW. 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE)	7286

[LLLL.]XXXX. Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(I) Any compound structurally derived from 3-(1-naphthoyl)indole or 1Hindol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Including, but not limited to:

- (a) AM2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole 7201
- (b) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole
- (c) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole
- (d) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole 7118
- (e) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole 7019
- (f) JWH-073, or 1-butyl-3-(1-naphthoyl)indole 7173
- (g) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole 7081
- (h) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
- (i) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole 7122
- (j) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole
- (k) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole 7200
- (l) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole
- (m) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole 7398

(II) Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;

(III) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;

(IV) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

- (a) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole
- (b) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole 7203
- (c) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole 6250
- (d) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole
- (e) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole 7008

(V) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited to:

(a) CP 47,497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol, where side chain n=5, and homologues where side chain n-4, 6, or 7 7297, 7298

(VI) Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

(a) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole 7694

(b) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-19 and RCS-4) 7104

(VII) CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

(VIII) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

(IX) HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

(X) Dimethylheptylpyran, or DMHP.

5. Depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

A. Gamma-hydroxybutyric acid and other names GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutonic acid; sodium oxybate; sodium oxybutyrate 2010

B. Mecloqualone 2572

C. Methaqualone 2565

6. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following

substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

A. Aminorex 1585

Some trade or other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-phenyl-2-oxazolamine;

B. N-benzylpiperazine (some other names: BZP, 1-benzylpiperzaine) 7493

C. Cathinone (Some trade or other names: 2-amino-1-phenyl-1-propanone, alphaaminopropiophenone, 2-aminopropiophenone and norephedrone) 1235

D. 4,4'-Dimethylaminorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine) 1595

E. Fenethylamine 1503

F. Methcathinone 1237

Some trade or other names: 2-(methylamino)-propiophenone; alpha-(methylamino) propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and URI 432;

G. 4-methoxymethcathinone

H. cis-4-methylaminorex (cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine) 1590

I. 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP

J. N-ethylamphetamine 1475

K. N,N-dimethylamphetamine 1480

(some other names: N,N-alpha-trimethylbenzeneethanamine; N,N-alpha-trimethylphenethylamine)

7. A temporary listing of substances subject to emergency scheduling under federal law shall include any material, compound, mixture, or preparation which contains any quantity of the following substances:

A. Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers. 9850

(I) Fentanyl-related substance means any substance not otherwise listed under another Administration Controlled Substance Code Number, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act 21 U.S.C. 355, that is structurally related to fentanyl by one (1) or more of the following modifications:

(a) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(b) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino, or nitro groups;

(c) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;

(d) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or

(e) Replacement of the N-propionyl group by another acyl group.

- [B. ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: 5F-EDMB-PINACA) 7036
- C. methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate, its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: 5F-MDMB-PICA) 7041
- D. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (trivial names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)) 7047
- E. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (trivial names: 5F-CUMYL-PINACA; SGT-25) 7083
- F. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers (trivial name: FUB-144) 7014
- G. N-Ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other name: 2-(ethylamino)-1-phenylhexan-1-one) 7246
- H. alpha-Pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names:  $\alpha$ -PHP; alpha-pyrrolidinohexiophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one) 7544
- I. 4-Methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one) 7245
- J. 4'-Methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one) 7446
- K. alpha-Pyrrolidinoheptanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one) 7548
- L. 4'-Chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro-alpha-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one) 7443
- M. N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: isotonitazene; N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine) 9614]
- [N.]B. 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers (Other names: bromphine; 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one) 9098
- C. 2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Butonitazene) 9751
- D. 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: Etodesnitazene; etazene) 9765
- E. N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Flunitazene) 9756
- F. N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metodesnitazene) 9764

**G. *N, N*-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Metonitazene) 9757**

**H. 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1*H*-benzimidazole, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other names: *N*-pyrrolidino etonitazene; etonitazepyne) 9758**

**I. *N, N*-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1*H*-benzimidazol-1-yl)ethan-1-amine, its isomers, esters, ethers, salts, and salts of isomers, esters and ethers (Other name: Protonitazene) 9759**

8. Khat, to include all parts of the plant presently classified botanically as *catha edulis*, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed, or extracts. 7032

(B) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.

1. Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or unless listed in another schedule, Schedule II shall include any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

A. Opium and opiate; and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone and their respective salts, but including the following:

(I) Raw opium	9600
(II) Opium extracts	9610
(III) Opium fluid	9620
(IV) Powdered opium	9639
(V) Granulated opium	9640
(VI) Tincture of opium	9630
(VII) Codeine	9050
(VIII) Dihydroetorphine	9334
(IX) Ethylmorphine	9190
(X) Etorphine hydrochloride	9059
(XI) Hydrocodone	9193
(XII) Hydromorphone	9150
(XIII) Metopon	9260
(XIV) Morphine	9300
(XV) Oripavine	9330
(XVI) Oxycodone	9143
(XVII) Oxymorphone	9652
(XVIII) Thebaine	9333

B. Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subparagraph (1)(B)1.A. of this rule shall be included in Schedule II, except that these substances shall not include the isoquinoline alkaloids of opium;

C. Opium poppy and poppy straw 9650

D. Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically

equivalent or identical with any of these substances, except that the substances shall not include:

(I) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; or

(II) Ioflupane;

E. Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy) 9670

2. Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan, and levopropoxyphene excepted:

A. Alfentanil	9737
B. Alphaprodine	9010
C. Anileridine	9020
D. Bezitramide	9800
E. Bulk Dextropropoxyphene (Non-dosage Forms)	9273
F. Carfentanil	9743
G. Dihydrocodeine	9120
H. Diphenoxylate	9170
I. Fentanyl	9801
J. Isomethadone	9226
K. Levo-alphaacetylmethadol	

Some other names: levo-alphaacetylmethadol, levomethadyl acetate, LAAM 9648

L. Levomethorphan	9210
M. Levorphanol	9220
N. Metazocine	9240
O. Methadone	9250
P. Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane	9254
Q. Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid	9802
R. Oliceridine (N-[(3-methoxythiophen-2-yl)methyl] ([2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro [4.5]decan-9-yl]ethyl]amine fumarate)	9245
S. Pethidine (Meperidine)	9230
T. Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine	9232
U. Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate	9233
V. Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid	9234
W. Phenazocine	9715
X. Piminodine	9730
Y. Racemethorphan	9732
Z. Racemorphan	9733
AA. Remifentanil	9739
BB. Sufentanil	9740
CC. Tapentadol	9780
DD. Thiafentanil	9729

3. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following

substances having a stimulant effect on the central nervous system:

- A. Amphetamine, its salts, optical isomers, and salts of its optical isomers 1100
- B. Lisdexamfetamine, its salts, isomers, and salts of its isomers 1205
- C. Methamphetamine, its salts, isomers, and salts of its isomers 1105
- D. Phenmetrazine and its salts 1631
- E. Methylphenidate 1724

4. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- A. Amobarbital 2125
- B. Glutethimide 2550
- C. Pentobarbital 2270
- D. Phencyclidine 7471
- E. Secobarbital 2315

5. Hallucinogenic substances:

- A. Nabilone 7379

Another name for nabilone: (±)trans-3-(1, 1-dimethylheptyl)-6, 6a,7,8,10,10a-hexahydro- 1-hydroxy-6, 6-dimethyl-9H-dibenzo(b,d) pyran-9-one.

B. Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration. (7365)

6. Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

A. Immediate precursor to amphetamine and methamphetamine:

- (I) Phenylacetone 8501

Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;

B. Immediate precursors to phencyclidine (PCP):

- (I) 1-phenylcyclohexylamine 7460
- (II) 1-piperidinocyclohexanecarbonitrile (PCC) 8603

C. Immediate precursor to fentanyl:

- (I) 4-anilino-N-phenethyl-4-piperidine (ANPP) 8333
- (II) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl) 8366

7. Any material, compound, mixture, or preparation which contains any quantity of the following alkyl nitrites:

- A. Amyl nitrite;
- B. Butyl nitrite.

(C) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

1. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

A. Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under 21 CFR 308.32 and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of

- controlled substances 1405
- B. Benzphetamine 1228
- C. Chlorphentermine 1645
- D. Clortermine 1647
- E. Phendimetrazine 1615

2. Depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

A. Any compound, mixture, or preparation containing –

- (I) Amobarbital 2126
- (II) Secobarbital 2316
- (III) Pentobarbital 2271

or any salt thereof and one (1) or more other active medicinal ingredients which are not listed in any schedule;

B. Any suppository dosage form containing –

- (I) Amobarbital 2126
- (II) Secobarbital 2316
- (III) Pentobarbital 2271

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

C. Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof

- D. Chlorhexadol 2510
- E. Embutramide 2020

F. Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomer, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act; 2012

G. Ketamine, its salts, isomer, and salts of isomers (some other names for ketamine:

- (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone) 7285

H. Lysergic acid 7300

I. Lysergic acid amide 7310

J. Methyprylon 2575

K. Perampanel, and its salts, isomers, and salts of isomers 2261

L. Sulfondiethylmethane 2600

M. Sulfonethylmethane 2605

N. Sulfonmethane 2610

O. Tiletamine and zolazepam or any salt thereof 7295

Some trade or other names for a tiletaminezolazepam combination product: Telazol.

Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6-8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, flupyrazapon.

- 3. Nalorphine 9400

4. Narcotics drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

A. Not more than one and eight tenths grams (1.8gm) of codeine per one hundred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium 9803

B. Not more than one and eight tenths grams (1.8gm) of codeine per one hundred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9804

C. Not more than one and eight tenths grams (1.8gm) of dihydrocodeine per one hundred milliliters (100 mL) or not more than ninety milligrams (90 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9807

D. Not more than three hundred milligrams (300 mg) of ethylmorphine per one hundred milliliters (100 mL) or not more than fifteen milligrams (15 mg) per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9808

E. Not more than five hundred milligrams (500 mg) of opium per one hundred milliliters (100 mL) or per one hundred grams (100 gm) or not more than twenty-five milligrams (25 mg) per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts 9809

F. Not more than fifty milligrams (50 mg) of morphine per one hundred milliliters (100 mL) or per one hundred grams (100 gm), with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts 9810

5. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

A. Buprenorphine 9064

6. Anabolic steroids. Unless specially excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation. DEA has assigned code 4000 for all anabolic steroids. Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, and ethers:

A. 3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane

B. 3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane

C. 5 $\alpha$ -androst-3,17-dione

D. 1-androstenediol

(3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene)

E. 1-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene)

F. 4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androst-4-ene)

G. 5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-androst-5-ene)

H. 1-androstenedione ([5 $\alpha$ ]-androst-1-en-3,17-dione)

I. 4-androstenedione (androst-4-en-3,17-dione)

J. 5-androstenedione (androst-5-en-3,17-dione)

K. Bolasterone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one)

L. Boldenone (17 $\beta$ -hydroxyandrost-1,4-diene-3-one)

M. Boldione (androstra-1,4-diene-3,17-dione)

N. Calusterone (7 $\beta$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one)

O. Clostebol (4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one)

P. Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst-1,4-dien-3-one)

Q. Desoxymethyltestosterone (17 $\alpha$ -methyl-5 $\alpha$ -androst-2-en-17 $\beta$ -ol) (a.k.a. madol)

R.  $\Delta$ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one)

S. 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one)

T. Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androst-3-one)

U. Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene)

V. Fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-en-3-one)

W. Formebolone (Formebolone) (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one)

X. Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano [2,3-c]-furazan)

Y. 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one

Z. 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one)

AA. 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one)

BB. Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-3-one)

CC. Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-3-one)

DD. Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one)

EE. Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene)

FF. Methasterone (2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androst-17 $\beta$ -ol-3-one)

GG. Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one)

HH. 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane

II. 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane

JJ. 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene

KK. 17 $\alpha$ -methyl-4-hydroxyandrost-4-ene (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-3-one)

LL. Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one)

MM. Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9,11-trien-3-one)

NN. Methyltestosterone (17 $\alpha$ -methyl-17-hydroxyandrost-4-en-3-one)

OO. Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one)

PP. 17 $\beta$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one) (a.k.a. 17 $\alpha$ -methyl-1-testosterone)

QQ. Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one)

RR. 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene)

SS. 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene)

TT. 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)

UU. 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene)

VV. 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene)

WW. 19-nor-4-androstenedione (estr-4-en-3,17-dione)

XX. 19-nor-5-androstenedione (estr-5-en-3,17-dione)

YY. Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one)

ZZ. Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one)



AAA. Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one)

BBB. Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one)

CCC. Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androst-3-one)

DDD. Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one)

EEE. Oxymetholone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-3-one)

FFF. Prostanazol (17 $\beta$ -hydroxy-5 $\alpha$ -androstano[3,2-c]pyrazole)

GGG. Stanolone ( $\Delta$ 1-dihydrotestosterone (a.k.a. 1-testosterone)(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one))

HHH. Stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-2-eno[3,2-c]-pyrazole)

III. Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-en-3-one)

JJJ. Testolactone(13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone)

KKK. Testosterone(17 $\beta$ -hydroxyandrost-4-en-3-one);

LLL. Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4,9, 11-trien-3-one)

MMM. Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one)

NNN. Any salt, ester, or isomer of a drug or substance described or listed in this subparagraph, if that salt, ester, or isomer promotes muscle growth except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration.

7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product 7369

(Some other names for dronabinol: (6aRtrans)- 6a,7,8,10a-tetrahydro-6.6.9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.)

(D) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this subsection. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

1. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

A. Not more than one milligram (1 mg) of difenoxin (DEA Drug Code No. 9168) and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit 9167

B. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) 9278

C. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol) 9752

D. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(I) Not more than two hundred milligrams (200 mg) of codeine per one hundred milliliters (100 mL) or per one hundred grams (100 gm);

(II) Not more than one hundred milligrams (100 mg) of dihydrocodeine per one hundred milliliters (100 mL) or per one hundred grams (100 gm); or

(III) Not more than one hundred milligrams (100 mg) of ethylmorphine per one hundred milliliters (100 mL) or per one hundred grams (100 gm).

2. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

A. Alfaxalone	2731
B. Alprazolam	2882
C. Barbitol	2145
D. Brexanolone	2400
E. Bromazepam	2748
F. Camazepam	2749
G. Carisoprodol	8192
H. Chloral betaine	2460
I. Chloral hydrate	2465
J. Chlordiazepoxide	2744
K. Clobazam	2751
L. Clonazepam	2737
M. Clorazepate	2768
N. Clotiazepam	2752
O. Cloxazolam	2753
<b>P. Daridorexant</b>	<b>2410</b>
[P.]Q. Delorazepam	2754
[Q.]R. Diazepam	2765
[R.]S. Dichloralphenazone	2467
[S.]T. Estazolam	2756
[T.]U. Ethchlorvynol	2540
[U.]V. Ethinamate	2545
[V.]W. Ethyl loflazepate	2758
[W.]X. Fludiazepam	2759
[X.]Y. Flunitrazepam	2763
[Y.]Z. Flurazepam	2767
[Z.]AA. Fospropofol	2138
[AA.]BB. Halazepam	2762
[BB.]CC. Haloxazolam	2771
[CC.]DD. Ketazolam	2772
[DD.]EE. Lemborexant	2245
[EE.]FF. Loprazolam	2773
[FF.]GG. Lorazepam	2885
[GG.]HH. Lormetazepam	2774
[HH.]II. Mebutamate	2800
[II.]JJ. Medazepam	2836
[JJ.]KK. Meprobamate	2820
[KK.]LL. Methohexital	2264
[LL.]MM. Methylphenobarbital (Mephobarbital)	2250
[MM.]NN. Midazolam	2884
[NN.]OO. Nimetazepam	2837
[OO.]PP. Nitrazepam	2834
[PP.]QQ. Nordiazepam	2838
[QQ.]RR. Oxazepam	2835
[RR.]SS. Oxazolam	2839
[SS.]TT. Paraldehyde	2585
[TT.]UU. Petrichloral	2591
[UU.]VV. Phenobarbital	2285
[VV.]WW. Pinazepam	2883
[WW.]XX. Prazepam	2764
[XX.]YY. Quazepam	2881
[YY.]ZZ. Remimazolam	2846
[ZZ.]AAA. Suvorexant	2223
[AAA.]BBB. Temazepam	2925
[BBB.]CCC. Tetrazepam	2886
[CCC.]DDD. Triazolam	2887
[DDD.]EEE. Zaleplon	2781
[EEE.]FFF. Zolpidem	2783

- [FFF.]GGG. Zopiclone 2784
3. Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
- A. Fenfluramine 1670
4. Lorcaserin. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
- A. Lorcaserin 1625
5. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
- A. Cathine ((+)-norpseudoephedrine) 1230
- B. Diethylpropion 1610
- C. Fencamfamin 1760
- D. Fenproporex 1575
- E. Mazindol 1605
- F. Mefenorex 1580
- G. Modafinil 1680
- H. Pemoline (including organometallic complexes and chelates thereof) 1530
- I. Phentermine 1640
- J. Pipradrol 1750
- K. Serdexmethylphenidate 1729
- L. Sibutramine 1675
- M. Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate (ester)) 1650
- N. SPA (-)-1-dimethylamino-1,2-diphenylethane 1635
6. Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts:
- A. Pentazocine 9709
- B. Butorphanol (including its optical isomers) 9720
- C. Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers 9725
7. Ephedrine. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including their salts, isomers, and salts of isomers:
- A. Ephedrine or its salts, optical isomers, or salts of optical isomers as the only active medicinal ingredient or contains ephedrine or its salts, optical isomers, or salts of optical isomers and therapeutically insignificant quantities of another active medicinal ingredient.
- (E) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this subsection.
1. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows, which shall include one (1) or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
- A. Not more than two hundred milligrams (200 mg) of codeine per one hundred milliliters (100 mL) or per one hundred grams (100 gm);
- B. Not more than one hundred milligrams (100 mg) of dihydrocodeine per one hundred milliliters (100 mL) or per one hundred grams (100 gm);
- C. Not more than one hundred milligrams (100 mg) of ethylmorphine per one hundred milliliters (100 mL) or per one hundred grams (100 gm);
- D. Not more than two and five-tenths milligrams (2.5 mg) of diphenoxylate and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit;
- E. Not more than one hundred milligrams (100 mg) of opium per one hundred milliliters (100 mL) or per one hundred grams (100 gm); and
- F. Not more than five-tenths milligram (0.5 mg) of difenoxin (DEA Drug Code No. 9168) and not less than twenty-five micrograms (25 mcg) of atropine sulfate per dosage unit.
2. Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system including its salts, isomers, and salts of isomers:
- A. Pyrovalerone 1485
3. Any compound, mixture, or preparation containing any detectable quantity of pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound, mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical isomers, or salts of optical isomers if the drug preparations are starch-based solid dose forms, if such preparations are sold over the counter without a prescription. The following drug preparations containing ephedrine and pseudoephedrine are not scheduled controlled substances:
- A. Drug preparations in liquid form;
- B. Drug preparations that require a prescription in order to be dispensed.
4. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:
- A. Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester] 2779
- B. Ganaxolone (3 $\alpha$ -hydroxy-3 $\beta$ -methyl-5 $\alpha$ -pregnan-20-one) 2401**
- [B.]C. Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide] 2746
- [C.]D. Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] 2782
- [D.]E. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (also referred to as BRV; UCB-34714; Briviact) 2710

[E.JF. Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl) pyridine-2-yl)-benzamide] 2790

[F.JG. Cenobamate ((1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl) carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester) 2720

*AUTHORITY:* section 195.015, RSMo Supp. [2021] **2022**, and section 195.195, RSMo 2016. Material found in this rule previously filed as 19 CSR 30-1.010. Original rule filed April 14, 2000, effective Nov. 30, 2000. For intervening history, please consult the **Code of State Regulations**. Emergency amendment filed Sept. 12, 2022, effective Oct. 3, 2022, expires March 31, 2023. A proposed amendment covering this same material is published in this issue of the **Missouri Register**.

*PUBLIC COST:* This emergency amendment will not cost state agencies or political subdivisions more than five hundred dollars (\$500) in the time the emergency is effective.

*PRIVATE COST:* This emergency amendment will not cost private entities more than five hundred dollars (\$500) in the time the emergency is effective.

**Title 19 – DEPARTMENT OF HEALTH AND SENIOR SERVICES**

**Division 30 – Division of Regulation and Licensure  
Chapter 20 – Hospitals**

**EMERGENCY RULE**

**19 CSR 30-20.144 Standards and Guidelines for Essential Caregiver Program**

*PURPOSE:* This rule establishes the standards and guidelines regarding the essential caregiver program established under section 191.2290, RSMo.

*EMERGENCY STATEMENT:* The “Essential Caregiver Program Act” became law on August 28, 2022. Under this new law, the department is required to develop standards and guidelines concerning the essential caregiver program. These standards and guidelines will provide the regulatory framework hospitals must follow to ensure that their patients have access to their designated essential caregivers. The standards and guidelines developed by the department must be operational during a state of emergency declared pursuant to Chapter 44, relating to infectious, contagious, communicable, or dangerous diseases. While there is no current declaration of a state of emergency, the implementing regulations for the Essential Caregiver Program Act should be in place prior to that potential event. It is imperative that this rule become effective as close to the same time that the law becomes effective in order to ensure that a hospital patient has immediate access to his or her essential caregiver, an indispensable member of the patient’s care team. As a result, the department finds a compelling governmental interest, which requires this emergency action. A proposed rule, which covers the same material, is published in this issue of the **Missouri Register**. The scope of this emergency rule is limited to the circumstances creating the

emergency and complies with the protections extended in the **Missouri and United States Constitutions**. The department believes this emergency rule is fair to all interested persons and parties under the circumstances. This emergency rule was filed September 15, 2022, becomes effective September 29, 2022, and expires March 27, 2023.

(1) As used in this rule, the following terms and phrases shall mean:

(A) Department shall mean the Department of Health and Senior Services;

(B) Essential caregiver shall mean a family member, friend, guardian, or other individual selected by a hospital patient who has not been adjudged incapacitated under chapter 475, or the guardian or legal representative of the patient;

(C) Hospital shall have the same meaning assigned to it 19 CSR 30-20.011(9).

(2) Every hospital within Missouri shall develop an essential caregiver program which shall allow a patient who has not been adjudged incapacitated under chapter 475, RSMo, a patient’s guardian, or a patient’s legally authorized representative to designate an essential caregiver for in-person contact with the patient in accordance with the provisions of section 191.2290, RSMo, and the standards and guidelines developed by the department under this rule.

(3) The essential caregiver program shall be operable during a state of emergency declared pursuant to chapter 44, RSMo, relating to infectious, contagious, communicable, or dangerous diseases.

(4) The essential caregiver program established by the hospital shall:

(A) Allow at least two individuals per patient to be designated as essential caregivers, although the hospital may limit the in-person contact to one caregiver at a time. The caregiver shall not be required to have previously served in a caregiver capacity prior to the declared state of emergency;

(B) Include a reasonable in-person contact schedule to allow the essential caregiver to provide care to the patient for at least four (4) hours each day, including evenings, weekends, and holidays, but shall allow for twenty-four-hour in-person care as necessary and appropriate for the well-being of the patient. The essential caregiver shall be permitted to leave and return during the scheduled hours or be replaced by another essential caregiver;

(C) Include procedures to enable physical contact between the patient and the essential caregiver. The hospital may not require the essential caregiver to undergo more stringent screening, testing, hygiene, personal protective equipment, and other infection control and prevention protocols than required of hospital employees; and

(D) Specify in its protocols the criteria that the hospital will use if it determines that in-person contact by a particular essential caregiver is inconsistent with the patient’s therapeutic care and treatment or is a safety risk to other patients or staff at the facility. Any limitations placed upon a particular essential caregiver shall be reviewed and documented every seven (7) days to determine if the limitations remain appropriate.

(5) A hospital shall inform, in writing, patients who have not been adjudged incapacitated under chapter 475, or guardians or legal representatives of patients, of the essential caregiver program and the process for designating an essential caregiver. Consistent with 42 CFR 482.12(h), a hospital shall inform each patient, or such patient’s guardian or legal representative, where appropriate, of his or her visitation rights and right to

access an essential caregiver in accordance with this rule.

(6) A hospital may restrict or revoke in-person contact by an essential caregiver who fails to follow required protocols and procedures established under section (4) of this rule.

(7) A hospital may request from the department a suspension of in-person contact by essential caregivers for a period not to exceed seven (7) days. A hospital may request from the department an extension of a suspension for more than seven (7) days, but such extension period shall not be for a period longer than seven (7) days at a time. Under the provisions of this section, a hospital shall not suspend in-person caregiver contact for more than fourteen (14) consecutive days in a twelve-month period or for more than forty-five (45) total days in a twelve-month period. Requests for a suspension of in-person contact of essential caregivers or an extension of a suspension under this section shall be submitted in writing to the department. Department determinations in response to suspension requests shall be in writing and both requests and determinations shall be made a part of the department's permanent records for the hospital.

(A) Requests for a suspension of in-person contact by essential caregivers shall contain at a minimum the following:

1. The specific reason or reasons why allowing in-person contact by essential caregivers poses a serious community health risk;
2. An explanation of the extenuating factors which may be relevant to granting a suspension to the particular requesting hospital; and
3. The length of time, not to exceed seven (7) days, the suspension is being requested.

(8) The department's written determination shall identify a suspension expiration date, if approved. The hospital may reapply for an extension of the suspension up to one (1) day prior to the expiration of the department's originally approved suspension. The department may deny a hospital's request to suspend in-person contact with essential caregivers if the department determines that such in-person contact does not pose a serious community health risk.

(9) The department shall suspend in-person contact by essential caregivers under this rule if it determines that doing so is required under federal law, including a determination that federal law requires a suspension of in-person contact by members of the patient's care team.

(10) The provisions of this rule shall not apply to those patients whose particular plan of therapeutic care and treatment necessitates restricted or otherwise limited visitation for reasons unrelated to the stated reasons for the declared state emergency.

(11) The provisions of this rule shall not be construed to require an essential caregiver to provide necessary care to a patient and a hospital shall not require an essential caregiver to provide necessary care.

*AUTHORITY: sections 191.2290 and 197.080, RSMo Supp. 2022. Emergency rule filed Sept. 15, 2022, effective Sept. 29, 2022, expires March 27, 2022. A proposed rule covering this same material is published in this issue of the **Missouri Register**.*

*PUBLIC COST: This emergency rule will cost state agencies or political subdivisions one hundred twenty-two thousand four hundred dollars (\$122,400) in the time the emergency is effective.*

*PRIVATE COST: This emergency rule will cost private entities four hundred thirty-eight thousand six hundred dollars (\$438,600) in the time the emergency is effective.*

**FISCAL NOTE  
PUBLIC COST**

- I. Department Title: Department of Health and Senior Services  
Division Title: Division 30—Division of Regulation and Licensure  
Chapter Title: Chapter 20 — Hospitals**

<b>Rule Number and Title:</b>	19 CSR 30-20.144 Standards and Guidelines for Essential Caregiver Program.
<b>Type of Rulemaking:</b>	Emergency Rulemaking

**II. SUMMARY OF FISCAL IMPACT**

Estimate of the number of entities by class which would likely be affected by the adoption of the rule:	Classification by types of the business entities which would likely be affected:	Estimate in the aggregate as to the cost of compliance with the rule by the affected entities:
36 public hospitals	<b>Public Hospitals</b>	<b>\$122,400.00</b>

**III. WORKSHEET**

**Cost for Private Hospitals to Adopt and Implement Essential Caregiver Programs**

Action	Explanation	Cost	Cost for Private Hospitals
Policy and procedure development, implementation, and training	Policy and Procedure Development-1FTE*8hrs=\$320 Implementation-1FTE*2hrs=80 Training-100 FTE*1hr=\$3000	\$3400	36 public hospitals * \$3400 = \$122,400

**IV. ASSUMPTIONS**

While it is generally assumed that most hospitals have already built into their operational costs the cost of updating their individual institutional policies and procedures to reflect changes made in law, this fiscal note attempts to breakdown the individual cost of complying with §191.2290, RSMo and the proposed emergency rule. In order to comply with the provisions of the proposed emergency rule, hospitals will have to update their

visitation policies to incorporate the essential caregiver guidelines and standards established by the proposed emergency rule.

This fiscal note also assumes that a state of emergency under Chapter 44, RSMo, relating to infectious diseases, has not been declared and is not in place. Even though the Department does not expect a state of emergency to be declared or in place during the time period of this emergency rule, the Department does expect public hospitals to adopt and implement policies to be in compliance with the provisions of the emergency rule. Of course, the steps taken by public hospitals to implement policies and train personnel to be consistent with the essential caregiver emergency rule will have a fiscal impact.

The department licenses approximately 36 public hospitals. The Department estimates that each public hospital will incur approximately \$3,400 in costs in developing the policies and procedures for the implementation of this emergency rule.

**FISCAL NOTE  
PRIVATE COST**

- I. Department Title: Department of Health and Senior Services  
Division Title: Division 30—Division of Regulation and Licensure  
Chapter Title: Chapter 20 — Hospitals**

<b>Rule Number and Title:</b>	19 CSR 30-20.144 Standards and Guidelines for Essential Caregiver Program.
<b>Type of Rulemaking:</b>	Emergency Rulemaking

**II. SUMMARY OF FISCAL IMPACT**

Estimate of the number of entities by class which would likely be affected by the adoption of the rule:	Classification by types of the business entities which would likely be affected:	Estimate in the aggregate as to the cost of compliance with the rule by the affected entities:
<b>129</b>	<b>Private Hospitals</b>	\$438,600.00 for 6 month period that a state of emergency is in effect (assumes no state of emergency has been declared or is in place)

**III. WORKSHEET**

**Cost for Private Hospitals to Adopt and Implement Essential Caregiver Programs**

Action	Explanation	Cost	Cost for Private Hospitals
Policy and procedure development, implementation, and training	Policy and Procedure Development-1FTE*8hrs=\$320 Implementation-1FTE*2hrs=80 Training-100 FTE*1hr=\$3000	\$3400	129 private hospitals * \$3400 = \$438,600.00

**IV. ASSUMPTIONS**

While it is generally assumed that most hospitals have already built into their operational costs the cost of updating their individual institutional policies and procedures to reflect changes made in law, this fiscal note attempts to breakdown the individual cost of complying with §191.2290, RSMo and the proposed emergency rule. In order to comply with the provisions of the proposed emergency rule, hospitals will have to update their visitation policies to incorporate the essential caregiver guidelines and standards established by the proposed emergency rule.

This fiscal note also assumes that a state of emergency under Chapter 44, RSMo, relating to infectious diseases, has not been declared and is not in place. Even though the Department does not expect a state of emergency to be declared or in place during the time period of this emergency rule, the Department does expect private hospitals to adopt and implement policies to be in compliance with the provisions of the emergency rule. Of course, the steps taken by private hospitals to implement policies and train personnel to be consistent with the essential caregiver emergency rule will have a fiscal impact.

The department licenses approximately 129 private hospitals (hospitals not owned by state or local governments). The Department estimates that each private hospital will incur approximately \$3,400 in costs in developing the policies and procedures for the implementation of this emergency rule.